For instance, DCs transfected with prostate-specific antigen (PSA) TAA mRNAs were administered to prostate cancer patients, which elicited a PSA-specific T-cell response and a significant decrease in PSA levels in six of seven patients [71]. The gene discussed is KLK3; the disease is prostate carcinoma.